Projects and Alliances

Molecular Diagnostics

Hutman Diagnostics AG

Svobi brought together a Czech originating technology and Swiss investors resulting in the launching of Hutman Diagnostics AG, a company dedicated to

"develop and commercialize the next generation diagnostic kits for rapid, reliable and specific identification of pathogens responsible for serious and life-threatening infections".

The technology platform is based on reverse hybridization of labelled bacterial DNA with specific oligonucleotide probes on a low-density microarray. This allows for the detection of hundreds of pathogens in a one shot device.

Svobi partners manage the Hutman Diagnostics development and technologisations of DNA based diagnostic kits - Xenia as COO and Quality Officer, Michal as Technology, IP, and Clinical Oficer.

Novel Biocatalyst Immobilization Technology

Svobi has become a value added partner of the technology company Lentikats^® under a distribution and cooperation contract with the technology owner and provider. Lentikats^® immobilization technology has already been used on industrial scale in water treatment for effective removal of nitrogen and in the food industry.

Svobi is developing industrial and research application of the Lentikats^® in life sciences and biotechnology industry, with focus on pharmaceutical API and intermediates for pharmaceutical industry.

Svobi is looking for the industrial partners and specialists in life science for the application development and implementation.

New Topical Delivery Platform to be Used with Difficult to Combine Active Ingredients.

A rational analysis of the therapeutic needs in dermatology has lead to the suggestion of several dermatologic preparations based on combination of known actives and or one chemical entity to be combinated with the natural products. These active ingredients are, however, believed to be incomatible in the dosage form.

Having extensive experience in formulating stable combinations of ingrediends believed to be incompatible, Svobi is now undertaking to solve the pharmaceutical chalenge of creating stable preparation of the pharmacologicaly synergetic, but chemicaly incompatible actives.

Svobi is working on this project in cooperation with academia and a distribution company. The future products, both RX and OTC, are of interests of specialized companies and distributors.

Svobi is looking for industrial and distribution partners worldwide.